BRIACELL THERAPEUTICS CORP. Stockholders' Equity Attributable to Noncontrolling Interest
BRIACELL THERAPEUTICS CORP. (BCTX) had Stockholders' Equity Attributable to Noncontrolling Interest of -$649.10 thousand as of 2026-04-30, per its 10-Q filed 2026-06-09.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:MinorityInterest · last filed 2026-06-09
- 2026-04-30: Stockholders' Equity Attributable to Noncontrolling Interest -$649.10K.
- 2026-01-31: Stockholders' Equity Attributable to Noncontrolling Interest -$702.63K.
- 2025-10-31: Stockholders' Equity Attributable to Noncontrolling Interest -$627.56K.
- 2025-07-31: Stockholders' Equity Attributable to Noncontrolling Interest -$546.79K.
| Period end | Stockholders' Equity Attributable to Noncontrolling Interest |
|---|---|
| 2026-04-30 | -$649.10K 10-Q · filed 2026-06-09 |
| 2026-01-31 | -$702.63K 10-Q · filed 2026-03-10 |
| 2025-10-31 | -$627.56K 10-Q · filed 2025-12-11 |
| 2025-07-31 | -$546.79K 10-Q · filed 2026-06-09 |
| 2025-04-30 | -$474.06K 10-Q · filed 2025-06-16 |
| 2025-01-31 | -$376.03K 10-Q · filed 2025-03-12 |
| 2024-10-31 | -$329.62K 10-Q · filed 2024-12-16 |
| 2024-07-31 | -$302.52K 10-K · filed 2025-10-16 |
| 2024-04-30 | -$267.94K 10-Q · filed 2024-06-14 |
| 2024-01-31 | -$244.42K 10-Q · filed 2024-03-18 |
| 2023-10-31 | -$205.11K 10-Q · filed 2023-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |